Myocardial dysfunction related to trastuzumab therapy – is effective treatment always possible?

Apply

Myocardial dysfunction related to trastuzumab therapy – is effective treatment always possible?

Journal Title: OncoReview - Year 2014, Vol 4, Issue 2

Abstract

Left ventricle systolic dysfunction manifesting during trastuzumab treatment is defined as cardiotoxicity type II. It is characterized by full reversibility after discontinuation of trastuzumab and cardiological pharmacological treatment. In a group of patients, however, systolic cardiac function does not fully recover. The reasons of this unfavorable prognosis are subject of heated discussion.

Authors and Affiliations

Sebastian Szmit, Łukasz Kownacki, Adam Torbicki

Keywords

Trastuzumab cardiotoxicity type II breast cancer

Results of a multi-centre survey concerning the treatment of hormone-dependent breast cancer in Poland in 2009–2013

In order to present a reliable picture of hormone-dependent breast cancer treatment in Poland, an on-line survey has been conducted in 19 oncology centres. As a result, data on the treatment of 486 patients have been obt...

Badanie kliniczne III fazy oceniające zastosowanie ewerolimusu w leczeniu rozsianego raka nerkowokomórkowego Wyniki końcowe i analiza czynników prognostycznych

Analiza etapowa w badaniu III fazy wykazała przewagę ewerolimusu nad placebo u chorych na rozsianego raka nerkowokomórkowego (mRCC), u których postęp choroby nastąpił w trakcie leczenia inhibitorami kinazy tyrozynowej na...

EP ID EP67753
DOI -
Views 172
Downloads 0